by Rod Raynovich | May 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The pre-ASCO hype has already begun but many biopharma stocks have already run up 15%+ YTD. So it is time to be cautious as there may be an “ASCO Effect”- a sell on the news effect. Despite a weak tape in the major indices the life science sector has a lot...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
M&A Premium Rocks On In a flat life science market eclipsed by the LinkedIn (LNKD) IPO and its day trading frenzy, many life science stocks in the Rayno Life Science Portfolio logged decent gains. As reported earlier today GenProbe(GPRO) sold off down 4.37% but it...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company...
by Rod Raynovich | May 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation chat is driving up shares of GenProbe (GPRO) on heavier volume of 2.5M shares. Two stories are notable one from the Wall Street Journal on ThermoFisher (TMO) a potential bidder, but also interested in Phadia AB an allergy testing Co., and the other on a...
by Rod Raynovich | May 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
M&A Premium of Diagnostic Companies Bloomberg reported on April 29 that GenProbe (GPRO) was seeking a buyer. We reported earlier this month on the M&A trend in biotechnology, tools and diagnostics and we will begin following the sector looking for value and...
by Rod Raynovich | May 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Deals Are Bullish for the Market Yesterday’s Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for the current M&A activity is: technologies and pipeline fit...
by Rod Raynovich | May 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph, Macro
Biotechs Rally Unphased by Macro Concerns The market loved the jobs report after the nasty commodity meltdown yesterday but other news intervened and buyers left for the weekend. The Dow was up as much as 175 pts and is now trying to hold 12637 up 55 pts. The S&P...
by Rod Raynovich | May 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Sector Steps Back after Meteoric Rise Since Early March With many life science indices reaching new highs both YTD and in some cases over 10 years traders decided it was time to put away some cash. Don’t fret yet as we are still way above March...
by Rod Raynovich | May 2, 2011 | 2024-25 Life Science Portfolios, BIOgraph
According to data compiled by the Wall Street Journal on Monday May 2 page R8, the Health and Biotechnology sectors led the market (excluding gold oriented funds) in 2011 up 13.2% YTD and 6.7% in April.In the number two position was small cap growth up 13% and mid cap...
by Rod Raynovich | Apr 29, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government cuts in government scientific spending especially NIH. Leerink Swann...
